David F. McDermott, M.D., is Director of the Biologic Therapy and Cutaneous Oncology Programs at Beth Israel Deaconess Medical Center (BIDMC), Leader of the Dana Farber/Harvard Cancer Center (DF/HCC) Kidney Cancer Program and co-Principal Investigator of the National Cancer Institute, Specialized Programs of Research Excellence (SPORE) grant, focusing on kidney cancer. Dr. McDermott is Director of the Cytokine Working Group, an innovator in the field of solid tumor immunotherapy and Professor of Medicine at Harvard Medical School. Dr. McDermott is a nationally and internationally recognized oncologist, clinical researcher and expert in three fields of research and clinical management: cancer immunotherapy, melanoma and kidney cancer. Dr. McDermott has particular interest in therapies that enhance the immune response to cancer. His immunotherapy research has focused on approaches to improve the therapeutic index of interleukin-2 and developing “targeted” immunotherapies for patients with solid tumors. Dr. McDermott has served on the Program Committee for the American Society of Clinical Oncology, the Medical Advisory Board for the Kidney Cancer Association, the National Cancer Institute Genitourinary Steering Committee and currently serves on the Kidney Cancer Task Force of the National Cancer Institute.